Clinical features of benign epilepsy of childhood with centrotemporal spikes in Chinese children

Meng-Jia Liu, MD, a,b Xiao-jun Su, MD, a,b Xiu-Yu Shi, MD, a,b Ge-fei Wu, MD, a Yu-qin Zhang, MD, a Li Gao, MD, a Wei Wang, MD, b Jian-xiang Liao, MD, a Hua Wang, MD, a Jian-ning Mai, MD, a Jing-yun Gao, MD, a Xiao-mei Shu, MD, k Shao-ping Huang, MD, l Li Zhang, MD, m Li-Ping Zou, MD, PhD a,b,∗

Abstract
This multicenter clinical trial was conducted to examine current practice of benign epilepsy with centrotemporal spikes and especially address the question that in what circumstances 1 antiepileptic drug (AED) should be preferred.

Twenty-five medical centers participate in this clinical trial. The general information, clinical information, and treatment status were collected under the guidance of clinicians and then analyzed. Difference between different treatment groups was compared, and usefulness of the most commonly used AEDs was evaluated.

A total of 1817 subjects were collected. The average age of the subject was 8.81 years. The average age of onset is 6.85 years (1–14 years). Male-to-female ratio is 1.13:1. A total of 62.9% of the patients are receiving monotherapies, and 10.6% are receiving multidrug therapy. Both age and course of disease of treated rolandic epilepsy (RE) patients are significantly different from those of untreated patients. Bilateral findings on electroencephalography (EEG) are less seen in patients with monotherapy compared with patients with multidrug therapy. Except for 25.4% patients not taking any AEDs, oxcarbazepine (OXC), sodium valproate (VPA), and levetiracetam (LEV) are the most commonly used 3 AEDs. VPA and LEV are commonly used in add-on therapy. OXC and LEV are more effective as monotherapy than VPA.

Age of onset of Chinese RE patients is 6.85 years. Bilateral findings on EEG could be a risk factor to require multidrug therapy. In Chinese patients, OXC, VPA, and LEV are most commonly used AEDs as monotherapy and OXC and LEV are more effective than VPA.

Abbreviations: AED = antiepileptic drug; BECTS = benign epilepsy of childhood with centrotemporal spikes; CSWS = cerebral salt wasting syndrome; EEG = electroencephalography; ESES = electrical status epilepticus in sleep; LEV = levetiracetam; LKS = Landau-Kleffner syndrome; MR = magnetic resonance; OXC = Oxcarbazepine; RE = rolandic epilepsy; VPA = Sodium valproate.

Keywords: antiepileptic drugs, BECTS, epilepsy

1. Introduction
Benign epilepsy with centrotemporal spikes (BECTS) is inherited childhood idiopathic focal epilepsy characterized by focal onset seizures (mostly partial motor seizures) and subtle cerebral structural abnormalities. BECTS accounts for 8% to 23% of childhood idiopathic focal epilepsy, and the male-to-female ratio is 6:4. The age of seizure onset is from 3 to 13 years, and the peak frequency occurs between 8 and 10 years. Seizure usually begins with unilateral tongue and perioral paresthesia, followed by facial tonic and/or clonic activity that may spread to the upper limb mostly during sleep. Age also significantly affects clinical course. Although some of the patients may exhibit minor cognitive and behavioral abnormalities, most of the abnormalities, including seizures, undergo long-lasting remission during adolescence, as...
revealed by electroencephalography (EEG) results. Thus, children with BECTS can avoid antiepileptic drug (AED) treatment. Small proportions of patients are resistant to AED treatment and may even progress to epileptic encephalopathy. “Idiopathic” indicates that the etiology of a condition is poorly understood; however, BECTS is highly related to inheritance. Approximately, 9% to 59% of patients with BECTS report a positive family history of seizures; chromosome 15q14 and N-acetylcholine receptor 27 subunit have been reported as suspicious causes.

There are widespread historical and geographical divergences in practice for BECTS patients.[1–4] Textbooks and expert suggestions advise no antiepileptic drugs in BECTS treatment.[5,6] Relationship between EEG spikes and cognitive disorders are still unresolved. Wolff et al.[7] reported that cognitive deficits may be associated with spike location, but not with spike rate in 20 children with IFE. Overvliet et al.[8] suggest the existence of relationship between cognitive deficits and nocturnal epileptic discharges in a comprehensive review. The relationship could be explained by disturbance of functional connectivity responsible for the corresponding cognitive disorders.[9,10] However, Nicolai et al.[11] reported that the correlation between cognitive deficits and locations of EEG is not conclusive. According to the above-mentioned evidence, the benign nature has been reconsidered allowing for the learning and memory impairment and regional function disruption that could be associated with focal EEG spikes.[12,13] Thus, the discrepancies of treatment versus nontreatment still exist and the evidence for favorable AEDs in practice is still unknown. Studies with large sample size of Chinese children with BECTS have yet to be performed. In our study, clinical information was collected from 2234 patients admitted to multiple medical centers, including 14 institutions in north China and 12 institutions in south China. We aim to examine current practice of BECTS and demonstrate what proportion of patients is not treated. We specially address the question in what circumstances 1 AED should be preferred to help establish comprehensive management of BECTS.

2. Methods

2.1. Study population

We collected information regarding the children diagnosed with BECTS from 25 pediatric neurological centers across China from September 2011 to January 2014. Inclusion criteria were as follows: patients diagnosed according to the International League Against Epilepsy (1989) diagnostic criteria of BECTS[1–4]; patients whose EEG results (ictal and interictal) showed positive- and negative-spike slow complex waves and sharp slow complex waves from unilateral or bilateral middle temporal, posterior temporal, and central regions with arrhythmic interictal activity; and patients whose EEG results revealed these waves sometimes accompanied with sharp spikes in other regions.[11] Complete clinical data were available. All of the patients completed the provided participant consent forms, and this study has been approved by the local ethics committee of PLA general hospital. Exclusion criteria were as follows: patients exhibiting non-epileptiform seizures and patients suffering from other systematic diseases and receiving related medications.

2.2. Data collection

The following information must be provided by the patients: neurological examination, head magnetic resonance, long-range sleep EEG, and other pertinent data. The patients and their parents completed the corresponding general information forms and informed consent forms under the guidance of clinicians. The following general information was obtained: sex, age of data collection, age of onset, family history, diagnosis, and treatment status. Monotherapy was defined as treatment with 1 AED; add-on therapy was described as treatment with additional AEDs to enhance the therapeutic effects; multidrug therapy was defined as simultaneous treatment with >2 AEDs. Radiographic abnormalities were classified into intracranial cyst, subtle abnormalities in cerebral ventricle, and mild abnormalities in white matter on the basis of magnetic resonance imaging findings. EEG manifestation was classified into unilateral and bilateral epileptiform discharge on the basis of the results of long-range sleep EEG. Course of disease is defined as duration since diagnosis.

2.2.1. Consensus process for EEG and MR evaluation. Every patient should undergo MR and EEG examinations. MR images and EEG results are allocated to radiologists or neurologists selected from junior panel and experienced panel, both. They all have formal radiologists or neurologists’ qualification certificate and evaluate MR and EEG results based on medical records. Disagreements across radiologists and neurologists will be discussed and consensus achieved in all cases.

2.3. Data analysis

Population characteristics and clinical features were analyzed. The general information and clinical features of the treated patients were compared with those of the untreated patients. The general information and clinical features of the patients subjected to monotherapy were compared with those of the patients treated with multidrug therapy. The components of AEDs used for monotherapy and add-on therapy were analyzed. The commonly used AEDs for multidrug therapy were evaluated.

2.4. Statistical analysis

For continuous variables, results were described as mean ± standard deviation. Student t test and Kruskal–Wallis test were performed to assess the differences. For categorical variables, differences were evaluated through χ² test. All analyses were conducted in SPSS 19.0 (SPSS Inc, Chicago, IL). The recorded P values were 2-sided, and P values of <0.05 were considered statistically significant.

3. Results

3.1. Population characteristics

Among the 2234 patients diagnosed with BECTS from 25 centers, 417 were excluded because of nonstandard information and 1817 were included for further analysis. Their general information is listed in Table 1. The age of data collection is 8.81 ± 2.7 years (2–19 years). The age of onset is 6.85 ± 2.45 years (1.92–14 years). Among the patients, 963 are males and 854 are females. The male-to-female ratio is 1.13:1. The age of data collection among male patients is 8.85 ± 2.69 years, and the age of data collection among female patients is 8.77 ± 2.7 years. The ages of onset in male and female patients are 6.89 ± 2.46 and 6.73 ± 2.77 years, respectively. The age of onset does not significantly differ between male and female patients (t = 1.017, P = 0.309). The family histories of 179 (9.9%) patients are positive. Mild radiographic abnormalities are found in 62 (3.4%) patients, but they are not related to BECTS. Of these patients, 20 exhibit...
intracranial cyst, 14 show mild abnormalities in the cerebral ventricle, and 20 manifest abnormalities in the white matter (Fig. 1). According to long-range sleep EEG reports from 1253 (69%) patients, unilateral discharge occurs in the Rolandic region in 889 (70.1%) patients, bilateral discharge exists in the Rolandic region in 364 (29.0%) patients, and electrical status epilepticus in sleep (ESES) manifests in 28 (2.23%) patients.

3.2. Treatment status
Among the 1817 patients, 416 (25.4%) did not receive any AED, 1143 (62.9%) received monotherapy, 192 (10.6%) underwent multidrug therapy, and 66 (3.63%) received irregular medication (Fig. 2).

3.3. Difference between our study and foreign studies on demographic features and treatment status
The above-mentioned results about demographic features and treatment status are compared with foreign studies (conducted in America,[16] Brazil,[17] and Israel[18]) to see whether our results support the previous studies or not, and the comparison is shown in Table 2.

3.4. Difference in clinical features between treated and untreated patients
Of the 466 untreated (25.4%) patients, 252 are males and 209 are females. Of the 1356 (74.6%) treated patients, 711 are males and 645 are females. The treated patients significantly differed from the untreated patients ($\chi^2 = 0.678$, $P = 0.407$). Of the untreated patients, 50 reported a positive family history of seizures and 411 described a negative family history. Of the treated patients, 129 showed a positive family history and 1227 displayed a negative family history. The family history of seizures did not significantly differ between the 2 groups ($\chi^2 = 0.688$, $P = 0.407$). The numbers of the patients who manifest abnormalities manifest abnormalities

### Table 1

| General information and population characteristics. |
|-----------------------------------------------------|
| N (1817) |
| Sex | Male/female | 963 (53.0%)/854 (47.0%) |
| Age of data collection, y | 8.81 (2–19) |
| Age of onset, y | 6.73 (1.92–14) |
| Disease course, y | 1.31 (0.08–7) |
| Mild radiographic abnormalities | 62 (3.4%) |
| Family history of seizures | 179 (9.9%) |
| EEG | Bilateral | 364 (29.1%) |
| | Unilateral | 889 (70.9%) |
| | ESES | 28 (2.2%) |
| Treatment status | Monotherapy | 1143 (62.9%) |
| | Multidrug therapy | 192 (10.6%) |
| | Other | 21 (1.1%) |
| | Untreated | 461 (25.4%) |

EEG = electroencephalograph, ESES = electrical status epilepticus in sleep.

### Table 2

| Comparison of studies on BECTS in children conducted in China and foreign countries. |
|----------------------------------------|
| Variables | Our study (n = 1817) | Vega’s[16] study in United States (n = 108) |
| Demographics | | |
| Age of data collection | 8.81 (2–19) | 9.5 (3–22) |
| Age of onset | 6.85 (±2.45) | 6.84 (±2.45) |
| Male/female | 963/854 | 61/47 |
| Treatment status | | |
| No AEDs | 416 (25.4%) | 32 (30%) |
| Monotherapy | 1143 (62.9%) | 51 (47%) |
| Multidrug therapy | 192 (10.6%) | 25 (23%) |
| Irregular medication | 66 (3.63%) | |
| EEG | | |
| Unilateral discharge | 889/364 | 70/24 |
| Bilateral discharge | Our study (n = 1817) | Tovia’s[18] study in Israel (n = 196) |
| ESES | 28 (2.23%) | 9 (4.6%) |

AED = antiepileptic drug, BECTS = benign epilepsy of childhood with centrotemporal spikes, EEG = electroencephalograph, ESES = electrical status epilepticus in sleep.
in radiographic findings of the untreated and treated groups are 14 and 53, respectively, but these numbers did not significantly differ ($\chi^2 = 0.736, P = 0.391$). Of the 286 untreated patients with EEG results, 196 and 90, respectively, manifested unilateral and bilateral discharges, as revealed by ictal sleep EEG. Of the 967 treated patients with EEG results, 693 and 274, respectively, experienced unilateral and bilateral discharges. Despite these findings, the two groups did not significantly differ in terms of EEG results ($\chi^2 = 1.051, P = 0.305$). The ages of onset in the untreated and treated patients are 6.73 ± 2.38 and 6.80 ± 2.48 years, respectively, but this finding did not also significantly differ between the 2 groups ($t = 0.555, P = 0.579$). The ages of data collection in the untreated and treated patients are 6.47 ± 2.47 and 9.58 ± 2.30 years, respectively, and these results significantly differed between the 2 groups ($t = 24.461, P < 0.001$). The courses of disease are 1.31 ± 1.82 and 2.24 ± 2.11 years in the untreated and treated patients, respectively. These findings also significantly differed between the 2 groups ($t = 8.377, P < 0.001$; Table 3).

### 3.5. Difference between monotherapy and multidrug therapy

Of the total number of patients, 1143 received monotherapy and 192 underwent multidrug therapy. The monotherapy group comprises 602 male and 541 female patients. The multidrug therapy group includes 102 males and 90 females. The sex composition of the 2 groups did not significantly differ ($\chi^2 = 0.014, P = 0.907$). The family history of seizures is positive in 111 patients and negative in 1129 patients in the monotherapy group. This parameter is positive in 17 patients and negative in 175 patients in the multidrug therapy group. Nevertheless, the family history of seizures did not significantly differ between the 2 groups ($\chi^2 = 0.139, P = 0.709$). Of the patients with abnormalities in radiographic results, 39 and 14 belong to the untreated and treated groups, respectively, but this finding did not significantly differ between the 2 groups ($\chi^2 = 6.49, P = 0.011$). Of the 806 monotherapy patients whose EEG results are available, 588 show unilateral discharge and 218 exhibit bilateral discharges. Of the 146 multidrug therapy patients whose EEG results are available, 93 and 53 patients display unilateral and bilateral discharges, respectively, and there is significant difference between the 2 groups ($\chi^2 = 5.199, P = 0.023$). The rate of bilateral discharge from the Rolandic region in the multidrug therapy group is definitely higher than that in the monotherapy group.

The ages of onset in monotherapy and multidrug therapy groups are 6.84 ± 2.47 and 6.72 ± 2.43 years, respectively, but this parameter did not significantly differ between the 2 groups ($t = 0.307, P = 0.759$). The ages of data collection in monotherapy and multidrug therapy groups are 9.07 ± 2.66 and 8.80 ± 2.76 years, respectively. This parameter did not also significantly differ between the 2 groups ($t = 1.327, P = 0.185$). The disease courses in monotherapy and multidrug therapy groups are 2.12 ± 2.08 and 2.93 ± 2.15 years, respectively, and this finding significantly differed between the 2 groups ($t = 5.199, P = 0.023$). The disease course in the multidrug therapy group is significantly higher than that in the monotherapy group (Table 4).

### 3.6. AEDs used in monotherapy

The AEDs used in monotherapy are oxcarbazepine (OXC), sodium valproate (VPA), levetiracetam (LEV), carbamazepine, lamotrigine, topiramate, and magnesium valproate. Among these AEDs (Fig. 3), the most commonly used are OXC 418 (37%), VPA 288 (25%), and LEV 216 (19%).

### 3.7. Clinical features of patients receiving monotherapy and add-on therapy

The first AED administered to 418 patients is OXC, and 29 of these patients use add-on drugs when OXC fails. A total of 288 patients use VPA as the first AED, and 89 of these patients receive add-on drugs when VPA fails. The first AED given to 215 patients is LEV, and 35 of these patients take add-on drugs when LEV fails. The rates of add-on therapy significantly differed among the 3 groups existing ($\chi^2 = 49.081, P < 0.001$). After post-hoc multiple comparisons were performed (Fig. 4), the following

---

**Table 3**

Clinical features between treated and untreated patients.

|                  | Untreated (n = 461) | Treated (n = 1356) | P     |
|------------------|---------------------|-------------------|-------|
| Female           | 209 (45.3%)         | 645 (47.6%)      | 0.407 |
| Bilateral discharge | 90 (31.5%)       | 274 (28.3%)      | 0.305 |
| Mild radiographic abnormalities | 14 (3%)         | 53 (3.9%)       | 0.391 |
| Family history of seizures | 50 (10.8%)       | 129 (9.5%)      | 0.407 |
| Age of onset, y  | 6.73 ± 2.38         | 6.80 ± 2.48      | 0.597 |
| Age of data collection, y | 6.49 ± 2.47     | 9.59 ± 2.31      | <0.001|
| Course of disease, y | 1.31 ± 1.82     | 2.42 ± 2.11      | <0.001|

EEG results are available in 1253 patients, 286 patients are untreated and 90 of them show bilateral discharge; 967 are treated, and 274 show bilateral discharge.

**Table 4**

Clinical features of patients in monotherapy and multidrug therapy group.

|                  | Monotherapy (N = 1143) | Multidrug therapy (N = 192) | P     |
|------------------|-------------------------|-----------------------------|-------|
| Female           | 541 (40.5%)             | 90 (46.9%)                  | 0.907 |
| Bilateral discharge | 218 (27.0%)            | 53 (36.3%)                  | 0.023 |
| Mild radiographic abnormalities | 39 (3.4%)         | 14 (7.3%)                   | 0.011 |
| Family history of seizures | 111 (9.7%)       | 17 (8.9%)                   | 0.139 |
| Age of onset, y  | 6.84 ± 2.47             | 6.72 ± 2.43                 | 0.759 |
| Age of data collection, y | 9.07 ± 2.66     | 8.79 ± 2.76                 | 0.185 |
| Course of disease, y | 2.12 ± 2.08     | 2.93 ± 2.14                 | <0.001|

The rate of bilateral discharge and radiographic abnormalities in multidrug therapy group is significantly higher than monotherapy group. Age of data collection in multidrug therapy group is longer than monotherapy group, and course of disease is longer.

---

**Figure 3**

Antiepileptic drugs used in monotherapy for rolandic epilepsy patients.
results significantly differed: OXC vs. VPA ($\chi^2=48.852, P<0.001$); VPA vs. LEV ($\chi^2=8.745, P=0.003$); and OXC vs. LEV ($\chi^2=10.850, P=0.001$).

3.8. Most commonly used AED combination

Among the multidrug therapies administered to 192 patients (Fig. 5), the most common AED combinations are LEV+VPA (46, 24.5%), OXC+VPA (26, 13.5%), VPA+lamotrigine (13, 6.8%), LEV+Topiramate (9, 4.7%), other 2-drug combinations (18, 4.7%), and 3-drug combinations (18, 4.7%). The most commonly used AEDs in the AED combinations are VPA (118, 61.5%), LEV (100, 52.1%), and OXC (60, 31.3%).

4. Discussion

This multicenter study aims to analyze the treatment status and the following clinical features of Chinese patients with BECTS: vulnerable age, male/female ratio, radiographic manifestations, and EEG characteristics. Among the 2234 patients with BECTS collected from 25 neurologic centers, 1817 with complete information were included and further analyzed. The age of onset of the study population is 6.85 years (1.92–14 years). This finding is consistent with that in previous studies, which revealed that the peak incidence occurred between 7th and 8th year of life\[19\]; previous research also indicated that morbidity is related to age.\[20\] The male-to-female ratio is 963 (53.0%)/854 (47.0%), consistent with the previously reported male-to-female ratio of

---

Figure 4. Add-on therapy/monotherapy ratio in the 3 most commonly used antiepileptic drugs. LEV = levetiracetam, OXC = oxcarbazepine, VPA = sodium valproate

Figure 5. Antiepileptic drugs combinations in multidrug therapy.
Kleffner syndrome. The frequency is reported to be 4.6% in to be related to age and could occur in many diseases, such as important role in the ef these AEDs. Therefore, whether bilateral discharge can play an response to different AEDs, such as CBZ, VPA, and OXC, but 25 30 patients with unilateral electrical activity elicit the same features of previously reported BECTS. Furthermore, 70.1% located in other regions. These results are consistent with the EEG middle and posterior temporal regions with arrhythmic activity; these waves are sometimes accompanied by sharp spike waves and 29% display bilateral electrical activities. The frequency of bilateral epileptic discharges is consistent with previous studies. Bedoin et al reported that 60% of the BECTS patients show unilateral discharge. Riva et al reported that 16 of 24 patients (66.7%) show unilateral discharge. No definite relationship has been observed between the number of epileptic discharges and the frequency of clinical seizures. A frequent epileptic discharge unlikely corresponds to a high frequency of clinical seizures. Pavlou et al reported that 30% patients with unilateral electrical activity elicit the same response to different AEDs, such as CBZ, VPA, and OXC, but 25 patients with bilateral electrical activity respond differently to these AEDs. Therefore, whether bilateral discharge can play an important role in the efficacy of AEDs remains unknown. In our study, 2.2% of the subjects show ESES, which has been shown to be related to age and could occur in many diseases, such as rolandic epilepsy, cerebral salt wasting syndrome, and Landau-Kleffner syndrome. The frequency is reported to be 4.6% in another study, which is a little different from our study and this could be because of the different inclusion criteria.

Considering the benign prognosis and spontaneous remission of BECTS, researchers have yet to obtain a consensus on whether AEDs can be administered to patients with BECTS. In our study, 25.4% (416) of the 1817 subjects did not receive AEDs. If clinical manifestations are subtle and neuropsychological abnormalities are nonexistent, treatment with AEDs can be postponed. In addition to the clinicians’ assessment of the patients, children’s and their parents’ willingness should be considered when deciding whether AED therapy should be given. In theory, the treatment should not cause neurological sequela because of the benign prognosis of BECTS. However, the risk of neuropsychological disorder in patients with BECTS is higher than that of the general population. Neuropsychologists claim that patients with BECTS usually show normal IQ, but they manifest mild disorders in language, visual space capability, and social ability, which should also be considered. The rate and pathogenesis of cognitive functions, such as language delay and learning disorder, have yet to be fully investigated. Furthermore, seizures and AEDs can be susceptible risk factors because some AEDs can induce cognitive dysfunction. Previous studies confirmed the relationship of seizures, their frequency, location, and other features with cognitive functions, but different studies have provided inconclusive findings. The patients who did not receive AEDs in this study suffer from low-frequency subtle seizures, which unlikely affect their daily lives. However, some subtle cognitive dysfunctions may have been overlooked. Most of the subjects received AED treatment, but patients should receive AEDs under the following circumstances: early seizure onset; 6-month intervals between the first 3 seizures; secondarily generalized tonic–clonic seizure; and seizures during awake. After analyzing the difference between the treated and untreated groups, we found that most of the variables did not significantly differ, but the age of data collection and disease courses significantly differed. The age of data collection of the patients in the treated group was significantly larger and their disease course was longer than those of the patients in the untreated group. Considering that the age of data collection of the untreated group is close to the age of onset, we hypothesized that the patients of the untreated group are in early disease stages when these patients have not yet received their AED treatment. The average age of onset among patients with BECTS is 6 to 7 years. As children age and start schooling, seizures become a stressor, which prompts them to undergo AED treatment. This phenomenon could result in an older age of data collection in the treated group.

The rates of bilateral discharge and mild radiographic abnormalities were significantly higher and the disease course was significantly longer in the multidrug therapy group than those in the monotherapy group. Nevertheless, the differences in the other variables in this study were not significant. Considering that most of the BECTS patients remit during puberty, it is difficult to decide the effect of AEDs on epileptic discharge. However, there has been sufficient evidence that neuropsychological and cognitive disorders are related to epileptic discharges, and treatment of these discharges is beneficial to restoration of the related function. Multidrug group shows higher rate of bilateral discharge, this may be because of more serious neuropsychological disorders. Bilateral discharge in the Rolandoic region may adversely affect the efficacy of AEDs, and this finding is consistent with our result. Mild cerebral structural abnormalities in patients with BECTS have also been investigated. For example, Kim et al found that the cortex of patients with BECTS is thicker than healthy individuals. However, researchers revealed discrepancies on whether these mild radiographic abnormalities show any clinical significance. The disease course in the multidrug therapy group was longer because add-on drugs were administered after the first drug failed. The need for multidrug therapy indicates that seizures cannot be easily controlled. Approximately 2% of patients with BECTS cannot easily control their seizures, and some of them progress to epileptic encephalopathy. We failed to determine and classify the seizure prognosis of the patients into intractable epilepsy because the information provided by the patients in the multidrug therapy group was incomplete. However, we predicted that these patients are more disposed to epileptic encephalopathy and should be
taken good care of. Furthermore, some of the patients receiving monotherapy may have just started AED therapy and the efficacy of AED cannot be identified because this study is cross-sectional.

The most commonly used AED combination is VPA+LEV, and the most commonly used AEDs are VPA and LEV. VPA is a broad-spectrum and low-cost drug and thus suitable for long-term treatment.\(^{[39]}\) LEV is commonly used because of its excellent pharmacokinetic characteristics, drug tolerance,\(^{[16,17]}\) and low drug interaction.\(^{[40]}\)

Among the most commonly used AEDs, namely, OXC, LEV, and VPA, additional AEDs are most commonly added to VPA monotherapy and are least frequently administered to OXC monotherapy. Although our study is cross-sectional and we failed to obtain information regarding the time when patients started receiving monotherapy and add-on therapy and their seizure prognosis, we can predict that the effectiveness of OXC and LEV as first-line therapy is better than that of VPA in Chinese BECTS patients.

The evidence base for specific AEDs in BECTS patients is still unknown. We can see several studies supporting recommendations for specific AEDs treatment, such as VPA,\(^{[41,42]}\) OXC,\(^{[43]}\) LEV,\(^{[44]}\) CBZ,\(^{[45]}\) and we can also see studies against specific AEDs used in treatment for BECTS patients.\(^{[45,46]}\) Nowadays, the first-line AED in different countries diverges, for example, Sulthiane in Germany, Austria, and Israel\(^{[42,47]}\) sodium valproate in France, and levetiracetam in United States. Whether the most commonly used AED in China is reasonable still needs further investigations.

In this study, 18 subjects received other treatments, but most of these subjects preferred to terminate their AED treatments. As a consequence, seizures recur. Hence, patients should be informed of the importance of treatment compliance. And we can see no consequence, seizures recur. Hence, patients should be informed of the importance of treatment compliance.

In this multicenter cross-sectional study, clinical features, general information, and treatment status were analyzed. Nevertheless, we did not collect information on seizure prognosis and cognitive function because this study is cross-sectional. Most seizures happen during sleep, and the frequency of seizure is usually low, but these conditions may influence our results. This study provides a basis for future large-sample studies on Chinese patients with BECTS.

5. Conclusion

The average age of onset for Chinese children with BECTS is 6.85 years, and the age of 50% of vulnerable patients is between 5 and 9 years. The male-to-female ratio is 1.13:1. The ages of onset do not significantly differ between males and females. Furthermore, 25.4% of the patients did not receive AEDs, 62.9% received monotherapy, and 10.6% underwent multidrug therapy. The ages of data collection of the patients in the treated group are older and the disease courses are longer than those of the patients in the untreated group. Bilateral discharge in the Rolandic region and mild radiographic abnormalities may indicate the failure of monotherapy. The most commonly used AEDs for Chinese patients with BECTS are OXC, VPA, and LEV, and the effectiveness of OXC and LEV is better than that of VPA.

Acknowledgments

We gratefully acknowledge the assistance and cooperation of the staff of the following hospitals: Children’s Medical Center of PLA General Hospital, Capital Institute of Pediatrics, Beijing Children’s Hospital, Peking University First Hospital, Tianjin Children’s Hospital, Shengjing Hospital of China Medical University, Tangshan Women’s Children’s Hospital, Harbin Children’s Hospital, First Teaching Hospital of Jilin University, Qilu Hospital of Shandong University, Linyi People’s Hospital, Henan Province People’s Hospital, The Second Affiliated Hospital of Xi’an Jiaotong University, Children’s Hospital of Soochow University, The Children’s Hospital of Zhejiang University School of Medicine, Jiangxi Province Children’s Hospital, Wuhan Women and Children Care Center, Children’s Hospital of Fudan University, Xiangya Hospital Central South University, Guangdong General Hospital, Guangzhou Children’s Hospital, West China Women’s and Children’s Hospital, Fuzhou General Hospital of Nanjing Military Command, Quanzhou Children’s Hospital, and Affiliated Hospital of Zunyi Medical College.

References

[1] Rating D, Wolf C, Bast T. Sulthiane as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiane Study Group. Epilepsia 2000;41:1284–8.
[2] Gross-Selbeck G. Treatment of “benign” partial epilepsies of childhood, including atypical forms. Neuropediatrics 1995;26:45–50.
[3] Rating D. Treatment in typical and atypical rolandic epilepsy. Epileptic Disord 2000;2(Suppl 1):S69–72.
[4] Wierrol E, Shermar EM, Vannasilin R, et al. Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. J Child Neurol 2008;23:14–21.
[5] Ambrosotto G, Tassini CA. Antiepileptic drug treatment of benign childhood epilepsy with rolandic spikes: is it necessary? Epilepsia 1990;31:802–5.
[6] Peters JM, Camfield CS, Camfield PR. Population study of benign rolandic epilepsy: is treatment needed? Neurology 2001;57:537–9.
[7] Wolf C, Weiskopf N, Serra E, et al. Benign partial epilepsy in childhood: selective cognitive deficits are related to the location of focal spikes determined by combined EEG/MEG. Epilepsia 2003;46:1661–7.
[8] Overvliet GM, Besseling RMH, Vles JSH, et al. Nocturnal epileptiform EEG discharges, nocturnal epileptic seizures, and language impairments in children: review of the literature. Epilepsy Behav 2010;19:530–8.
[9] Lillywhite LM, Saling MM, Harvey AS, et al. Neuropsychological and functional MRI studies provide converging evidence of anterior language dysfunction in BECTS. Epilepsia 2009;50:2276–84.
[10] Besseling RMH, Jansen JFA, Overvliet GM, et al. Reduced functional integration of the sensorimotor and language network in rolandic epilepsy. NeuroImage Clin 2013;2:22–46.
[11] Nicolai J, Aldenkamp AP, Arends J, et al. Cognitive and behavioral effects of nocturnal epileptiform discharges in children with benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav 2006;8:56–70.
[12] Aarts JH, Binne CD, Smit AM, et al. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain 1984;107 (Pt 1):293–308.
[13] Khan OI, Zhao Q, Miller F, et al. Intercital spikes in developing rats cause long-standing cognitive deficits. Neurobiol Dis 2010;39:362–71.
[14] Proposal for revised classification of epilepsies, epileptic syndromes-Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389–99.
[15] Guerini R, Pellacani S. Benign childhood focal epilepsies. Epilepsia 2012;53(Suppl 4):9–18.
[16] Vega YH, Smith A, Cockrell H, et al. Risk factors for reading disability in families with rolandic epilepsy. Epilepsy Behav 2015;53:174–9.
[17] Mizia RS, Mantreza ML. Hemispheric lateralization in benign focal epilepsy in childhood with centrotemporal spikes (BECTS). Clinical EEG Neurosci 2010;41:147–50.
[18] Tovia F, Goldberg-Stern H, Zeve BB, et al. The prevalence of atypical presentations and comorbidities of benign childhood epilepsy with centrotemporal spikes. Epilepsia 2011;52:1483–8.
[19] Kriz M, Gazdik M. [Epilepsy with centrotemporal (Rolando) spikes. A peculiar seizure disorder of childhood]. Neurrol Neurochir Pol 1978;12:413–9.
[20] Kramer U, Ben-Zeev B, Harel S, et al. Transient oromotor deficits in children with benign childhood epilepsy with central temporal spikes. Epilepsia 2001;42:616–20.
[21] Watanabe K. Epilepsy in children. 1996;Chapman & Hall, London:302.
[22] Eeg-Olofsson O, Lundberg S, Raininko R. MRI in rolandic epilepsy. Epileptic Disord 2000;2(Suppl 1):S51–S53.
[23] Luo C, Zhang Y, Cao W, et al. Altered structural and functional feature of striato-cortical circuit in benign epilepsy with centrotemporal spikes. Int J Neural Syst 2015;25:1550027.
[24] Besseling RM, Overvliet GM, Jansen JF, et al. Aberrant functional connectivity between motor and language networks in rolandic epilepsy. Epilepsy Res 2013;107:253–62.
[25] Bedoin N, Herbillon V, Lamoury I, et al. Hemispheric lateralization of cognitive functions in children with centrotemporal spikes. Epilepsy Behav 2009;9:268–74.
[26] Pavlou E, Gkampeta A, Evangelou A, et al. Benign epilepsy with centrotemporal spikes (BECTS): relationship between unilateral or bilateral localization of interictal stereotyped focal spikes on EEG and the effectiveness of anti-epileptic medication. Hippokratia 2012;16:221–4.
[27] Binnie CD, Marston D. Cognitive and behavioral outcomes in benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav 2013;25:85–89.
[28] Cerminara C, Montanaro ML, Curatolo P, et al. Lamotrigine-induced cognitive functions and epileptic activity. Seizure 2000;9:184–90.
[29] Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551–63.
[30] Ioannidis JP, Mannion JF, Kwan P, et al. Levetiracetam vs. sulthiame in children with centrotemporal spikes: an open-label, parallel group trial. Brain Dev 2007;29:281–83.
[31] Seidel WT, Mitchell WG. Cognitive and behavioral effects of carbamazepine in children: data from benign rolandic epilepsy. J Child Neurol 1999;14:716–23.
[32] Borggraefe I, Bontert M, Rast T, et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). Eur J Paediatr Neurol 2013;17:507–14.